Positive topline results from the US Phase II study of ASC30 for the treatment of type 2 diabetes
October 29, 2026
Source: drugdu
28
Ascletis Pharma announced on the 29th that it has achieved positive top-line results in its Phase II US study evaluating the oral small-molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of type 2 diabetes. This Phase II study was a 13-week US study designed to evaluate the efficacy, safety, and tolerability of once-daily oral ASC30 tablets in 100 diabetic subjects.
Regarding the primary endpoint, ASC30 achieved a statistically significant and clinically meaningful reduction in glycated hemoglobin (HbA1c) in diabetic subjects compared to placebo (p < 0.0001). Based on the efficacy estimand, at week 12, the placebo-adjusted reduction in HbA1c from baseline (least squares mean) was 1.7%, 1.6%, and 1.7% in the 40 mg (n=20), 60 mg (n=29), and 80 mg (n=28) dose groups, respectively. The baseline mean HbA1c was 8.3%.
Source: https://finance.eastmoney.com/a/202610293912992532.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting October 29, 2026
- Chipscreen’s NW001, the World’s First Epigenetic Immune-Modulating Antibody Conjugate, Approved for Clinical Trials October 29, 2026
- Dongyangguang Pharmaceutical aims to be the first generic drug. October 29, 2026
- Following a collective trading halt, MicroPort Medical officially announced a change in leadership! October 29, 2026
- What new growth signals did Hengrui Medicine release in the third quarter? October 29, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
